Strongyloides hyperinfection is a life-threatening acceleration of the Strongyloides stercoralis autoinfective cycle, occurring almost exclusively in immunosuppressed hosts, with a case fatality rate of 60–87% even with treatment. [1-3] It is triggered most commonly by corticosteroid use or HTLV-1 coinfection, and can present decades after initial exposure. [4-5]
1. History
- Duration and character of GI symptoms: diarrhea (often bloody), abdominal pain, nausea, vomiting, anorexia, weight loss [1-2]
- Respiratory symptoms: cough, dyspnea, wheezing, hemoptysis [6]
- Skin: pruritus, migratory serpiginous urticaria (larva currens) — abdomen, buttocks, groin [5]
- Travel/residence history: tropics, subtropics, rural southeastern US, Appalachia, or any endemic region [7]
- Immigration/refugee status, barefoot soil contact, agricultural work
- Timing of immunosuppression onset: corticosteroids (even short courses), chemotherapy, biologics, transplant immunosuppression [1][6]
- Prior known Strongyloides infection or eosinophilia workup
- Ask about COVID-19 treatment with dexamethasone — cases of hyperinfection triggered by corticosteroids for COVID have been described [7-8]
2. Alarm Features
- Gram-negative bacteremia or meningitis in an immunosuppressed patient with GI/pulmonary symptoms — pathognomonic complication of hyperinfection (septic shock in ~50%, bacteremia in ~40%) [6]
- Respiratory failure / ARDS [1][9]
- GI bleeding (hematemesis, melena) [4][10]
- Ileus or intestinal obstruction [10-11]
- Altered mental status (CNS dissemination — meningitis, brain abscess) [1]
- Coagulopathy, multiorgan failure [1]
- Absence of eosinophilia in a patient on corticosteroids does NOT rule out hyperinfection — 70–100% of hyperinfection patients have normal eosinophil counts [6][12]
3. Medications
- Corticosteroids (any dose/duration) are the single most important trigger — even brief courses can precipitate hyperinfection (aOR 3.25 for severe disease) [4][12]
- Other immunosuppressants: vincristine, tacrolimus, mycophenolate, anti-TNF biologics, other immunomodulators [1][5]
- Ivermectin 200 µg/kg is the drug of choice [13-14]
- Chronic infection: single oral dose
- Hyperinfection: daily dosing continued for at least 2 weeks after documented larval clearance from all body fluids [13][15]
- If unable to tolerate oral: subcutaneous or rectal ivermectin (off-label) [15-16]
- Albendazole 400 mg PO BID for 10–14 days as alternative if ivermectin unavailable [15-16]
- Broad-spectrum antibiotics for concurrent Gram-negative sepsis (empiric coverage for enteric organisms) [1][6]
- Contraindicated: initiating or escalating corticosteroids without concurrent anthelmintic treatment in at-risk patients [7][17]
4. Diet
- NPO if ileus, obstruction, or hemodynamic instability
- Nutritional support is critical — severe malnutrition is both a risk factor and a consequence [1][11]
- Parenteral nutrition may be needed in disseminated disease with malabsorption
- Ensure adequate caloric and protein intake during recovery
5. Review of Systems
- GI: diarrhea, bloody stool, abdominal pain, bloating, nausea, vomiting, weight loss
- Pulmonary: cough, dyspnea, wheezing, hemoptysis, pleuritic chest pain
- Dermatologic: pruritus, urticaria, serpiginous rash (larva currens), perianal pruritus
- Neurologic: headache, neck stiffness, confusion (meningitis/CNS dissemination)
- Constitutional: fever, malaise, fatigue, night sweats
- Urologic: dysuria, hematuria (rare, disseminated)
6. Collateral History and Family History
- Country of origin and detailed travel history (even remote — infection can persist for decades) [4-5]
- Household contacts with similar symptoms or soil exposure
- HTLV-1 status of patient and sexual partners [4]
- Organ transplant donor history — donor-derived strongyloidiasis is well-documented (median onset ~13 weeks post-transplant) [6]
- Occupational exposure: farming, mining, construction with soil contact
- Alcohol use disorder — independently associated with severe disease [9]
7. Risk Factors
- Corticosteroid use — strongest predictor of severe disease [4][12]
- HTLV-1 coinfection — impairs Th2 response, promotes hyperinfection [4]
- Solid organ or hematopoietic stem cell transplant [6][16]
- Hematologic malignancies (lymphoma, leukemia) [5][9]
- Hypogammaglobulinemia [5]
- Severe malnutrition [1][11]
- Chronic kidney disease [11]
- Alcohol use disorder, liver cirrhosis [9]
- Residence in or travel to endemic areas (tropics/subtropics, rural southeastern US) [7]
- Notably, HIV/AIDS alone is NOT a strong risk factor for hyperinfection (unlike HTLV-1) [4]
8. Differential Diagnosis
- Gram-negative sepsis from other sources (urinary, biliary, pneumonia)
- Bacterial meningitis (enteric organisms in CSF should raise suspicion for Strongyloides)
- Eosinophilic pneumonia / Löffler syndrome from other helminths
- Tuberculosis (pulmonary infiltrates + immunosuppression)
- Invasive fungal infection (Aspergillus, Mucor) in immunocompromised hosts
- Inflammatory bowel disease (chronic GI symptoms, bloody diarrhea)
- GI malignancy — hyperinfection can mimic gastric outlet obstruction or malignancy [10]
- Other parasitic infections: hookworm, Ascaris, Entamoeba
- Vasculitis with pulmonary-renal involvement
9. Past Medical History
- Prior Strongyloides diagnosis or treatment (may have been inadequately treated)
- History of unexplained eosinophilia [17-18]
- Transplant history and immunosuppressive regimen [6]
- Hematologic malignancy or chemotherapy
- Autoimmune disease requiring chronic steroids
- Prior HTLV-1 testing
- History of recurrent urticaria or larva currens
10. Physical Exam
- Vitals: fever, tachycardia, hypotension (septic shock), tachypnea, hypoxia
- Skin: serpiginous urticarial tracks (larva currens) on abdomen/buttocks/groin; petechiae or purpura (disseminated) [5]
- Lungs: diffuse wheezing, crackles, signs of consolidation or ARDS
- Abdomen: diffuse tenderness, distension, absent bowel sounds (ileus), guarding (peritonitis), GI bleeding [6]
- Neuro: meningismus, altered mental status (CNS dissemination)
- Perianal: excoriations, pruritus
11. Lab Studies
- CBC with differential: eosinophilia may be present in chronic infection but is often absent in hyperinfection (suppressed by corticosteroids) — absence does not rule out disease [6][12]
- Blood cultures: Gram-negative bacteremia (E. coli, Klebsiella, Enterococcus) — present in ~40% of hyperinfection cases [6][12]
- Stool for ova and parasites: look for filariform (L3) larvae; single stool sensitivity is low (~30%); serial stool exams (×3–7) or agar plate culture (sensitivity ~89%) significantly improve yield [6]
- Strongyloides serology (IgG ELISA): sensitivity 75–94% in immunocompetent patients but reduced to 43–68% in immunocompromised hosts — cannot be used alone to rule out disease [6]
- Sputum examination: larvae may be found in respiratory secretions during hyperinfection [4][6]
- CSF analysis: if meningitis suspected — larvae and/or enteric organisms may be identified [6]
- CMP, lactate, coagulation studies: assess for end-organ damage, DIC
- HTLV-1 serology: essential in all cases [4]
- Stool PCR: available in some centers, sensitivity ~62%, specificity ~95% [6]
12. Imaging
- Chest X-ray: diffuse bilateral interstitial or alveolar infiltrates, pleural effusions; may show Löffler-type migratory infiltrates [2][5]
- CT chest: diffuse ground-glass opacities, consolidation, ARDS pattern
- CT abdomen/pelvis: bowel wall thickening, ileus, ascites, mesenteric lymphadenopathy; contrast-enhanced CT and MRI can determine gut damage [5]
- Plain abdominal X-ray: ileus, obstruction pattern
- Imaging is nonspecific but essential for assessing complications and guiding management
13. Special Tests
- Agar plate culture (APC): most sensitive stool-based method (~89%) — requires fresh stool and 48–72 hours [6]
- Baermann concentration technique: improved sensitivity over direct smear [1][5]
- Duodenoscopy with biopsy: can reveal eggs, larvae, and adult worms in duodenal mucosa — particularly useful when stool is negative [5][10]
- Bronchoalveolar lavage (BAL): larvae identifiable in respiratory specimens during hyperinfection [5-6]
- PCR of stool, blood, or CSF: available in specialized centers [5-6]
- Capsule endoscopy: rarely used but can identify worms
14. ECG
- No specific ECG findings for strongyloidiasis
- ECG indicated to evaluate for sepsis-related cardiac dysfunction, electrolyte abnormalities, or myocarditis
- Monitor for arrhythmias in the setting of septic shock and multiorgan failure
15. Assessment
Strongyloides hyperinfection is a medical emergency with mortality exceeding 60% even with treatment, and approaching 100% if untreated. [1][5] The syndrome results from uncontrolled autoinfection in immunosuppressed hosts, leading to massive larval burden, bowel wall penetration, and translocation of enteric bacteria causing polymicrobial sepsis. [1][6] Key distinguishing features:
- Gram-negative bacteremia/meningitis + immunosuppression + GI/pulmonary symptoms = high suspicion
- Can present decades after leaving an endemic area [4-5]
- Eosinophilia is often absent in hyperinfection — its presence is actually protective (associated with lower mortality) [12]
- Complications: septic shock, ARDS, DIC, meningitis, multiorgan failure [1][6][9]
16. Treatment Plan
Initial stabilization:
- Aggressive resuscitation: IV fluids, vasopressors if septic shock
- Intubation and mechanical ventilation for respiratory failure
- Broad-spectrum antibiotics covering enteric Gram-negatives (e.g., piperacillin-tazobactam or meropenem) [1][6]
Anthelmintic therapy:
- Ivermectin 200 µg/kg/day orally — continue daily until larvae are cleared from all body fluids, then for an additional 7–14 days after documented clearance [13][15-16]
- If oral absorption is compromised (ileus, malabsorption): subcutaneous ivermectin (veterinary formulation, off-label) or per-rectum administration [15-16]
- Albendazole 400 mg PO BID can be added as combination therapy or used as alternative [15-16]
- Reduce or discontinue immunosuppression whenever possible — this is critical [6-7]
Monitoring:
- Serial stool examinations (every 2–3 days) to document larval clearance [13][19]
- Repeat sputum/BAL if pulmonary involvement
- Follow blood cultures to clearance
- Monitor for immune reconstitution inflammatory syndrome (IRIS) if immunosuppression is reduced
17. Disposition
- All hyperinfection cases require ICU admission — high mortality, need for hemodynamic monitoring, ventilatory support, and close parasitologic follow-up [6][9]
- Infectious disease consultation is mandatory
- Consider tropical medicine or parasitology specialist consultation
- Transplant team involvement if post-transplant
- Patients with uncomplicated chronic strongyloidiasis can be treated outpatient with single-dose ivermectin and follow-up stool exams
18. Follow Up / Return Precautions
- Post-treatment monitoring: serial stool exams every 2 weeks for at least 4–6 weeks to confirm larval clearance (autoinfection cycle is ~2 weeks) [19]
- Serology may take 12–18 months to serorevert after successful treatment — not useful for acute monitoring [1]
- If immunosuppression must continue, consider secondary prophylaxis with ivermectin (two doses every 2 weeks for 6 weeks) [19]
- Screen all at-risk patients before initiating immunosuppression — empiric treatment with ivermectin if testing is not readily available [7-8]
- Return precautions: worsening abdominal pain, bloody stool, fever, dyspnea, confusion, or any new symptoms while on treatment
- Expected recovery in survivors is gradual; nutritional rehabilitation is essential
- Long-term follow-up with infectious disease for at least 6–12 months
References
1. Review of the WHO Guideline on Preventive Chemotherapy for Public Health Control of Strongyloidiasis. — Lo NC, Addiss DG, Buonfrate D, et al. The Lancet. Infectious Diseases. 2025.
2. Review of the WHO Guideline on Preventive Chemotherapy for Public Health Control of Strongyloidiasis. — Lo NC, Addiss DG, Buonfrate D, et al. The Lancet. Infectious Diseases. 2025.
3. Review of the WHO Guideline on Preventive Chemotherapy for Public Health Control of Strongyloidiasis. — Lo NC, Addiss DG, Buonfrate D, et al. The Lancet. Infectious Diseases. 2025.
4. Ivermectin Versus Albendazole or Thiabendazole for Strongyloides Stercoralis Infection. — Henriquez-Camacho C, Gotuzzo E, Echevarria J, et al. The Cochrane Database of Systematic Reviews. 2016.
5. Ivermectin Versus Albendazole or Thiabendazole for Strongyloides Stercoralis Infection. — Henriquez-Camacho C, Gotuzzo E, Echevarria J, et al. The Cochrane Database of Systematic Reviews. 2016.
6. Severe Strongyloidiasis: A Systematic Review and Meta-Analysis of 339 Cases. — Rojas OC, Montoya AM, Villanueva-Lozano H, Carrion-Alvarez D. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2023.
7. Severe Strongyloidiasis: A Systematic Review and Meta-Analysis of 339 Cases. — Rojas OC, Montoya AM, Villanueva-Lozano H, Carrion-Alvarez D. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2023.
8. Strongyloides Stercoralis in the Immunocompromised Population. — Keiser PB, Nutman TB. Clinical Microbiology Reviews. 2004.
9. Strongyloides Stercoralis in the Immunocompromised Population. — Keiser PB, Nutman TB. Clinical Microbiology Reviews. 2004.
10. Soil-Transmitted Helminth Infections. — Jourdan PM, Lamberton PHL, Fenwick A, Addiss DG. Lancet. 2018.
11. Soil-Transmitted Helminth Infections. — Jourdan PM, Lamberton PHL, Fenwick A, Addiss DG. Lancet. 2018.
12. Intestinal parasites including Cryptosporidium , Cyclospora , Giardia , and Microsporidia , Entamoeba histolytica , Strongyloides , Schistosomiasis, and Echinococcus : Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. — La Hoz RM, Morris MI, AST Infectious Diseases Community of Practice. Clinical Transplantation. 2019.
13. Intestinal parasites including Cryptosporidium , Cyclospora , Giardia , and Microsporidia , Entamoeba histolytica , Strongyloides , Schistosomiasis, and Echinococcus : Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. — La Hoz RM, Morris MI, AST Infectious Diseases Community of Practice. Clinical Transplantation. 2019.
14. Strongyloides Stercoralis. — Czeresnia JM, Weiss LM. Lung. 2022.
15. Strongyloides Stercoralis. — Czeresnia JM, Weiss LM. Lung. 2022.
16. Implementation and Outcomes of an Empiric Ivermectin Strongyloides Treatment Protocol for Patients Receiving High-Dose Corticosteroids for Severe COVID-19. — Swart B, Ahiskali A, Wolf JM, Shaughnessy M. The American Journal of Tropical Medicine and Hygiene. 2023.
17. Implementation and Outcomes of an Empiric Ivermectin Strongyloides Treatment Protocol for Patients Receiving High-Dose Corticosteroids for Severe COVID-19. — Swart B, Ahiskali A, Wolf JM, Shaughnessy M. The American Journal of Tropical Medicine and Hygiene. 2023.
18. Clinical Characteristics and Outcomes of Disseminated Strongyloidiasis in the United States-a Multicenter Network Analysis. — Henao-Martínez AF, Olivo Freites C, Agudelo Higuita NI, et al. The American Journal of Tropical Medicine and Hygiene. 2024.
19. Clinical Characteristics and Outcomes of Disseminated Strongyloidiasis in the United States-a Multicenter Network Analysis. — Henao-Martínez AF, Olivo Freites C, Agudelo Higuita NI, et al. The American Journal of Tropical Medicine and Hygiene. 2024.
20. Strongyloides Stercoralis: From Chronic Silent Infection to Fulminant Catastrophe. — Vinueza D, Collazos-Torres LA, Vallejo-Serna RA, et al. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases. 2026.
21. Strongyloides Stercoralis: From Chronic Silent Infection to Fulminant Catastrophe. — Vinueza D, Collazos-Torres LA, Vallejo-Serna RA, et al. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases. 2026.
22. Efficacy and Safety of Ascending Doses of Emodepside in Comparison With Ivermectin in Adults Infected With Strongyloides Stercoralis in Laos: A Phase 2a, Dose-Ranging, Randomised, Parallel-Group, Placebo-Controlled, Single-Blind Clinical Trial. — Taylor L, Many S, Jeanguenat H, et al. The Lancet. Infectious Diseases. 2025.
23. Efficacy and Safety of Ascending Doses of Emodepside in Comparison With Ivermectin in Adults Infected With Strongyloides Stercoralis in Laos: A Phase 2a, Dose-Ranging, Randomised, Parallel-Group, Placebo-Controlled, Single-Blind Clinical Trial. — Taylor L, Many S, Jeanguenat H, et al. The Lancet. Infectious Diseases. 2025.
24. Predictors of Severe Strongyloidiasis and Mortality in Hospitalized Patients From Southern Thailand. — Chittrakarn S, Tongsengkee N, Sangkakul N, Kanchanasuwan S. PLoS Neglected Tropical Diseases. 2026.
25. Predictors of Severe Strongyloidiasis and Mortality in Hospitalized Patients From Southern Thailand. — Chittrakarn S, Tongsengkee N, Sangkakul N, Kanchanasuwan S. PLoS Neglected Tropical Diseases. 2026.
26. Current Pharmacotherapeutic Strategies for Strongyloidiasis and the Complications in Its Treatment. — Buonfrate D, Rodari P, Barda B, et al. Expert Opinion on Pharmacotherapy. 2022.
27. Current Pharmacotherapeutic Strategies for Strongyloidiasis and the Complications in Its Treatment. — Buonfrate D, Rodari P, Barda B, et al. Expert Opinion on Pharmacotherapy. 2022.
28. FDA Drug Label. — Updated date: 2025-01-29. Food and Drug Administration.
29. FDA Drug Label. — Updated date: 2025-01-29. Food and Drug Administration.
30. Unravelling the Mystery: Abdominal Pain in a Solid Organ Transplant Recipient. — Fauzi SMM, Abad CL, Simkins J, et al. Transplant Infectious Disease : An Official Journal of the Transplantation Society. 2025.
31. Unravelling the Mystery: Abdominal Pain in a Solid Organ Transplant Recipient. — Fauzi SMM, Abad CL, Simkins J, et al. Transplant Infectious Disease : An Official Journal of the Transplantation Society. 2025.
32. A comprehensive review of Strongyloides stercoralis infection after solid organ and hematopoietic stem cell transplantation. — Abad CLR, Bhaimia E, Schuetz AN, Razonable RR. Clinical Transplantation. 2022.
33. A comprehensive review of Strongyloides stercoralis infection after solid organ and hematopoietic stem cell transplantation. — Abad CLR, Bhaimia E, Schuetz AN, Razonable RR. Clinical Transplantation. 2022.
34. Strongyloides Stercoralis Infection in a Patient Initiating Corticosteroid Therapy for Hypereosinophilia: A Case Report. — Uslu Ö, Demirel F, Aydoğ G, Dinç B, Taylan Özkan A. Parasitology International. 2025.
35. Strongyloides Stercoralis Infection in a Patient Initiating Corticosteroid Therapy for Hypereosinophilia: A Case Report. — Uslu Ö, Demirel F, Aydoğ G, Dinç B, Taylan Özkan A. Parasitology International. 2025.
36. Is Eosinophilia a Reliable Diagnostic Clue for Chronic Strongyloidiasis? A Case Series From Khuzestan Province, Iran. — Ashiri A, Rafiei A, Ansari B, Beiromvand M. BMC Infectious Diseases. 2025.
37. Is Eosinophilia a Reliable Diagnostic Clue for Chronic Strongyloidiasis? A Case Series From Khuzestan Province, Iran. — Ashiri A, Rafiei A, Ansari B, Beiromvand M. BMC Infectious Diseases. 2025.
38. Strongyloides stercoralis Infection in Alcoholic Patients. — Teixeira MC, Pacheco FT, Souza JN, et al. BioMed Research International. 2016.
39. Strongyloides stercoralis Infection in Alcoholic Patients. — Teixeira MC, Pacheco FT, Souza JN, et al. BioMed Research International. 2016.